PET Imaging of Pancreatic Dopamine D3/D2 receptor density with 11C (+)-PHNO in Type-1 Diabetes Mellitus.
Type-1 diabetes mellitus (T1DM) has traditionally been characterized by a complete destruction of beta-cell mass (BCM); however, there is growing evidence of possible residual BCM present in T1DM. Given the absence of in vivo tools to measure BCM, routine clinical measures of beta cell function (e.g., C-peptide release) may not reflect BCM. We previously demonstrated the potential utility of positron emission tomography (PET) imaging with the dopamine D2/D3-receptor agonist 11C-(+)-PHNO to differentiate between healthy control (HC) and T1DM individuals. Methods: Sixteen individuals participated (10M/6F; 9-HC/7-T1DM). Average duration of diabetes was 18±6y (range:14-30y). Individuals underwent PET/CT scanning with a 120-minute dynamic PET scan centered on the pancreas. One- and two-tissue compartment (1TC/2TC) models were used to estimate pancreas and spleen distribution volume (VT). Reference region approaches (spleen as reference) were also investigated. Quantitative PET measures were correlated with clinical outcome measures. Immunohistochemistry was performed to examine colocalization of dopamine receptors with endocrine hormones in HC and T1DM pancreatic tissue. Results: C-peptide release was not detectable in any T1DM individuals while proinsulin was detectable in 3/5 T1DM individuals. Pancreas SUVR-1 (20-30min; spleen as reference region) demonstrated a statistically significant reduction (-36.2%) in radioligand binding (HC:5.6, T1DM:3.6; P = 0.03). Age-at-diagnosis correlated significantly with pancreas SUVR-1 (20-30min) (R2=0.67, P = 0.025). Duration of diabetes was not significantly correlated with pancreas SUVR-1 (20-30 min) (R2=0.36, P = 0.16). Mean acute C-peptide response to arginine at maximal glycemic potentiation did not significantly correlate with SUVR-1 (20-30min) (R2=0.57, P = 0.05), nor did mean baseline proinsulin (R2=0.45, P = 0.10). Immunohistochemistry demonstrated co-localization of dopamine receptor type-3 (DRD3) and dopamine receptor type-2 (DRD2) in healthy controls. No co-localization of the DRD3 or DRD2 was seen with somatostatin, glucagon and polypeptide Y. In a separate T1DM individual, no immunostaining was seen with DRD3, DRD2 or insulin antibodies suggesting the loss of endocrine DRD3 and DRD2 expression accompanies the loss of beta cell functional insulin secretory capacity. Conclusion: 30min scan durations and SUVR-1 provide quantitative outcome measures for 11C-(+)-PHNO, a D3-receptor-preferring agonist PET radioligand, to differentiate BCM in T1DM and HCs.